6,Johnson M, Diasio R. Importance of dihydropyrimidine dehy- drogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzym Regul 2001; 41:151e7. 7,Amstutz U, Froehlich TK, Largiade`r CR. Dihydropyrimidine dehydrogenase gene as a major predictor ...
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol. 2007; 24 :251–8. doi: 10.1007/BF02698048. [ Cross Ref ]...
[6]Raida M,Schwabe W,Hausler P,et al.Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase(DPD)gene within the 5’-splice donor site of intron 14 in patients with severe 5-fluorouracil(5-FU)-related toxicity compared with controls[J].Clin Cancer Res,2001,7:2832-2839...
To date, a direct correlation between DPYD gene mutation and decreased 5-FU clearance has only been suggested but never been proven. In this study, we provide the first detailed analysis of 5-FU pharmacoki- netics in a patient with low DPD-activity due to heterozygosity for a mutant allele...
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients Article Open access 02 September 2015 A systematic review and meta-analysis of toxicity and treatment outcomes with pharma...
The patient lacked any additional toxic effect–associated variations in the DPYD gene or the thymidylate synthase (TYMS) promoter. This case suggests that Y186C may have contributed to 5-FU toxicity in this patient and supports the use of Y186C as a predictive marker for 5-FU toxic effects...
Dihydropyrimidine dehydrogenase (DPD), the initial and rate-limiting enzyme in the 5-fluorouracil (5-FU) catabolic pathway, has been implicated as one of t... Z Xue,L Lin,J Fourie,... - 《Biochimica Et Biophysica Acta Gene Structure & Expression》 被引量: 20发表: 2006年 SOX9, miR-495...
Dihydropyrimidine dehydrogenase enzyme (DPD) deficiency is a pharmacogenetic syndrome leading to severe side-effects in patients receiving therapies containing the anticancer drug 5-fluorouracil (5-FU). The aim of this population study is to evaluate gene variations in the coding region of the dihydro...
This variability, which is partially attributed to genetic defects of the DPD gene (DPYD), leads to differential responses of cancer patients, resistance to or increased toxicity of 5-FU (van Kuilenburg 2004). Complete DPD deficiency is also associated with the inherited metabolic disorder, ...
*Tempus Merlin was developed and is performed by Skyline Dx as a reference laboratory xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs...